Biodistribution and radiation dosimetry of [N-methyl- 11C]mirtazapine, an antidepressant affecting adrenoceptors

Applied Radiation and Isotopes

Volumn 59, Issue 2-3, 2003, Pages 175-179

  Marthi, Katalin ^a,b   Hansen, Søren B ^a   Jakobsen, Steen ^a   Bender, Dirk ^a   Smith, Stefan Bo ^a   Smith, Donald F ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

Author keywords

Antidepressant; Biodistribution; Dosimetry; Noradrenergic neurotransmission; PET; N methyl 11C Mirtazapine

Indexed keywords

IMAGING TECHNIQUES; ISOTOPES; RADIOLOGY;

NEUROIMAGING;

DOSIMETRY;

MIRTAZAPINE;

ADRENAL GLAND; ADRENERGIC ACTIVITY; ADULT; ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; FEMALE; GALLBLADDER MUCOSA; HUMAN; ISOTOPE LABELING; LUNG; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; SPLEEN; WHOLE BODY RADIATION;

EID: 0042521220     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8043(03)00156-8     Document Type: Article

References (14)

1. Anttila S.A., Leinonen E.V. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 7:2001;249-264.
2. Cristy, M., Eckerman, K., 1987. Specific absorbed fractions of energy at various ages from internal photon sources, I-VII. ORNL/TM-8381 V1-V7, Oak Ridge National Laboratory.
3. de Boer T. The pharmacologic profile of mirtazapine. J. Clin. Psychiatr. 57(Suppl 4):1996;19-25.
4. Eskandari F., Sternberg E.M. Neural-immune interactions in health and disease. Ann. NY. Acad. Sci. 966:2002;20-27.
5. Gibbs M.E., Summers R.J. Role of adrenoceptor subtypes in memory consolidation. Prog. Neurobiol. 67:2002;345-391.
6. Hentrich F., Gothert M., Greschuchna D. Noradrenaline release in the human pulmonary artery is modulated by presynaptic alpha 2-adrenoceptors. J. Cardiovasc. Pharmacol. 8:1986;539-544.
7. International Commission on Radiological Protection, 1997. ICRP Publication 80. Radiation dose to patients from radiopharmaceuticals, Addendum 2 to ICRP Publication 53, Annals of ICRP, Pergamon.
8. Kent J.M. SNaRIs, NaSSAs, and NaRIs. new agents for the treatment of depression Lancet. 355:2000;911-918.
9. 11C]Mirtazapine for PET neuroimaging. radiosynthesis and initial evaluation in the living porcine brain Eur. Neuropsychopharmacol. 12:2002;427-432.
10. Mejia A.A., Nakamura T., Masatoshi I., Hatazawa J., Masaki M., Watanuki S. Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. J. Nucl. Med. 32:1991;699-706.
11. Stabin M.G. MIRDOSE. personal computer software for internal dose assessment in nuclear medicine J. Nucl. Med. 37:1996;538-546.
12. Talbot P.S., Laruelle M. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur. Neuropsychopharmacol. 12:2002;503-511.
13. 18F]fluoroethyl)-L-tyrosine as oncologic PET tracer. Appl. Radiat. Isot. 58:2003;219-225.
14. Timmer C.J., Sitsen J.M., Delbressine L.P. Clinical pharmacokinetics of mirtazapine. Clin. Pharmacokinet. 38:2000;461-474.